Compare FirstEnergy Corp. (FE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Inovio Pharmaceuticals Inc — how do they compare? FirstEnergy Corp. trades at $44.84 (market cap $25.95B), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $112.19M). The key difference: FirstEnergy Corp. is far larger — about 231.3× Inovio Pharmaceuticals Inc's market cap, and FirstEnergy Corp. pays a 4.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FE | INO | |
|---|---|---|
Market Cap | $25.95B | $112.19M |
Volume | 5,643,833 | 3,201,278 |
Sector | Utilities | Health |
52-Week High | $51.91 | $2.65 |
52-Week Low | $43.04 | $0.66 |
Typical Hold Time | 71 Days | 43 Days |
Enterprise Value | $54.87B | $83.51M |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% with a bullish technical signal despite mixed earnings. The utility shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though recent quarters saw two EPS misses. Analyst consensus is Moderate Buy with a $52.80 target, while institutional interest grows with recent purchases by Nykredit and Corient Private Wealth.
FE offers stable utility operations with dividend support, but faces execution risks from its $36B Energize365 plan and rising debt. The stock's 8.4% upside to target and 4.2% dividend yield appeal to income investors, though high RSI suggests near-term pressure. Regulatory approvals and data-center demand are key catalysts.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
